alpha-glucosidase Inhibitors
1 drugsAbout alpha-glucosidase
Alpha-glucosidase, located in the small intestine, breaks down complex carbohydrates into glucose. This enzyme plays a key role in carbohydrate metabolism and postprandial glucose levels.
Inhibiting alpha-glucosidase is a therapeutic strategy for managing type 2 diabetes by reducing postprandial hyperglycemia. Currently, there is no genetic evidence directly linking alpha-glucosidase to specific diseases.
Miglitol is the only FDA-approved drug targeting alpha-glucosidase, available as a small molecule. Westminster Pharmaceuticals is the sole company with an approved alpha-glucosidase inhibitor.
Top alpha-glucosidase Drugs
Westminster Pharmaceuticals is the only company with an approved drug.
The lack of competition suggests high barriers to entry or limited market potential.
alpha-glucosidase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha-glucosidase, using small molecule modality.
Exploring alternative modalities could provide a competitive advantage in this space.
alpha-glucosidase Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alpha-glucosidase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha-glucosidase Drug Approval Timeline (2015 - 2015)
The first and only drug, Miglitol, was approved in 2015.
The stagnant approval timeline indicates a potentially saturated market or lack of innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alpha-glucosidase. A trial counts if an approved drug acting on alpha-glucosidase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.